Skip to main content
Terug
Watch Compare

Kyverna Therapeutics, Inc.

Datakwaliteit: 83%
KYTX
Nasdaq Manufacturing Chemicals
€ 8,95
▼ € 0,63 (-6,58%)
Marktkapitalisatie: 567,07 M
Prijs
€ 9,38
Marktkapitalisatie
567,07 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -153,72 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-95,92%
Onder sectorgemiddelde (-53,41%)
ROIC-78,92%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio5,16
Interest Coverage-347,29

Waardering

PE (TTM)
-3,52
Onder sectorgemiddelde (-1,48)
P/B Ratio3,73
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -3,5 -1,5
P/B 3,7 1,6
ROE % -95,9 -53,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

ETFs Holding This Stock

BRUSX BRUSX
1,16% weight
BRSIX BRSIX
0,11% weight
GSCYX GSCYX
0,00% weight
GSCZX GSCZX
0,00% weight
AVSC logo AVSC Avantis U.S. Small Cap Equity ETF
0,00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -161,31 M
ROE -95,92% ROA -77,99%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -153,72 M
ROIC -78,92% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 5,16
Interest Coverage -347,29 Asset Turnover N/A
Working Capital 141,05 M Tangible Book Value 151,95 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3,52 Forward P/E N/A
P/B Ratio 3,73 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -27,11%
Market Cap 567,07 M Enterprise Value 532,91 M
Per Share
EPS (Diluted TTM) -3,64 Revenue / Share N/A
FCF / Share -2,54 OCF / Share -2,54
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 95,29%
SBC-Adj. FCF -163,37 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024
Revenue — —
Net Income -161,31 M -127,48 M
EPS (Diluted) -3,64 -3,33
Gross Profit — —
Operating Income -169,83 M -142,60 M
EBITDA — —
R&D Expenses 133,72 M 112,47 M
SG&A Expenses — —
D&A 1,80 M 2,13 M
Interest Expense 489.000,0 142.000,0
Income Tax 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024
Total Assets 293,83 M 304,65 M
Total Liabilities 61,55 M 38,06 M
Shareholders' Equity 232,28 M 266,59 M
Total Debt — —
Cash & Equivalents 124,09 M 96,62 M
Current Assets 282,95 M 290,60 M
Current Liabilities 36,49 M 33,76 M